Identifying biomarkers for response to radiation therapy in soft tissue sarcoma patients
[RADIOSARC] Searching for Specific Gene Signature(s) of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Adults Patients With Resectable Soft Tissue Sarcomas of Limbs
This study is trying to find specific markers in tumor samples from soft tissue sarcoma patients to see how well they respond to radiation therapy, with the hope of improving treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Leon Berard Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Lyon) |
| Trial ID | NCT05739084 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to identify transcriptomic biomarkers that predict sensitivity and resistance to neoadjuvant radiotherapy (RT) in patients with resectable soft tissue sarcomas (STS). By analyzing tumor samples, the study seeks to uncover biological mechanisms that contribute to radioresistance, which could help personalize RT schedules for better patient outcomes. The research will involve high-throughput approaches to explore the molecular targets that may be inhibited to overcome intrinsic resistance to radiation. The ultimate goal is to improve treatment strategies for STS patients undergoing RT.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed soft tissue sarcomas who have available tumor samples.
Not a fit: Patients with metastatic soft tissue sarcoma or those receiving neoadjuvant systemic treatments will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective radiation therapy for patients with soft tissue sarcomas.
How similar studies have performed: While the approach of identifying biomarkers for radiation response is being explored, this specific study focuses on a novel aspect of soft tissue sarcomas and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female ≥ 18 years at time of non-opposition to participate to the study * Patient with documented non-opposition to participate to the study. * Patient with histologically and cytologically confirmed diagnosis with STS (..) * Patient with availability of FFPE tumor block from initial diagnosis biopsy (mandatory) and surgery specimen (optional). * Patients with tumor FFPE samples prepared with the last 4 years * Patient with evaluable tumor sample meeting the following quality/quantity control criteria (..) Exclusion Criteria: * Patients with metastatic soft tissue sarcoma at diagnosis * Patients with exclusive radiotherapy without surgical resection * Patients receiving neo adjuvant systemic treatment (chemotherapy, immunotherapy, targeted therapy)
Where this trial is running
Lyon
- Centre Léon Bérard — Lyon, France (Recruiting)
Study contacts
- Study coordinator: Marie -Pierre SUNYACH, MD
- Email: MariePierre.SUNYACH@lyon.unicancer.fr
- Phone: +33(0)4 78 78 28 28
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.